Document text
Principal Investigator: Barton F. Haynes
Organization: DUKE UNIVERSITY
Fiscal Year: 2021
Award: $3,622,426
Funding agency: National Institute of Allergy and Infectious Diseases
Administrative Core
The IPCAVD Administrative Core will serve to coordinate all scientific and administrative activities of the Duke
IPCAVD, ensuring that the Projects and Cores function well together. A primary activity of the Core will be
monitoring IPCAVD progress relative to milestones and measuring this progress against available funding to
ensure resources are used efficiently. The Core will coordinate the effort of an External Advisory Committee
(EAC) that will review the progress of the Projects and Cores and provide critical guidance for the Program's
direction. Core staff are part of a highly experienced and integrated management team, which will enable
immediate start-up and rapid progress. This teamwork will accelerate advancement toward the Program's
goals, thus maximizing the opportunities to positively impact HIV-1 vaccine research in humans. The Specific
Aims of the Administrative Core are as follows.
Aim 1. Provide overall IPCAVD management, coordination and supervision of the Program.
Aim 2. Ensure timely financial accounting and reporting.
Aim 3. Ensure compliance with all institutional, state, and federal research and CGMP guidelines.
Aim 4. Develop and implement an IPCAVD communication, publication, and data sharing plan.
Aim 5. Provide statistical support for all data analyses.
The IPCAVD Administrative Core will facilitate the successful integration of Project 1, Project 2, and the Animal
Models Core to support the overall Program goal to develop two mRNA clinical trials materials for testing in a
Phase 1 clinical trial in year 5. As an optimally functioning Core, it will support development of nucleoside-
modified mRNAs an important new HIV-1 vaccine platform that potentially can transform the HIV-1 vaccine
field by providing immunogens to initiate bnAb lineages and induce durable immune responses.
Terms: <AIDS Virus><Accounting><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Advisory Committees><Agreement><Animal Model><Animal Models and Related Studies><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Budgets><Cell Lineage><Clinical Trials><Collaborations><Communication><Contracting Opportunities><Contracts><Data><Data Analyses><Data Analysis><Data Provenance><Development><Early-Stage Clinical Trials><Ensure><Expenditure><Experimental Designs><Financial Management><Food and Drug Administration><Funding><Glycans><Glycopeptides><Goals><Grant><Guidelines><HIV><HIV-1><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><IACUC><Immune response><Immunological response><Infrastructure><Institutional Animal Care and Use Committee><Institutional Policy><Investigators><LAV-HTLV-III><Lead><Letters><Lymphadenopathy-Associated Virus><Materials Testing><Measures><Messenger RNA><Modern Man><Monitor><NIH><National Institutes of Health><Nucleosides><Occupational activity of managing finances><Outcome><Participant><Pb element><Personnel Staffing><Phase 1 Clinical Trials><Phase I Clinical Trials><Policies><Polysaccharides><Practice Guidelines><Preparation><Production><Protocol><Protocols documentation><Publications><Regulation><Reporting><Research><Research Personnel><Research Resources><Researchers><Resources><Rights><Risk><Scientific Publication><Supervision><Task Forces><Testing><Time><USFDA><United States Food and Drug Administration><United States National Institutes of Health><Universities><Vaccine Research><Virus-HIV><advisory team><conflict resolution><data interpretation><data management><data sharing><developmental><expectation><experience><heavy metal Pb><heavy metal lead><host response><immune system response><immunogen><immunoresponse><mRNA><meetings><member><model of animal><model organism><monomer><phase I protocol><programs><quality assurance>